Al-Ayadhi Laila, Zayed Naima, Bhat Ramesa Shafi, Moubayed Nadine M S, Al-Muammar May N, El-Ansary Afaf
Department of Physiology, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia.
Autism Research and Treatment Center, Riyadh, Saudi Arabia.
Gut Pathog. 2021 Sep 13;13(1):54. doi: 10.1186/s13099-021-00448-y.
Innovative research highlighted the probable connection between autism spectrum disorder (ASD) and gut microbiota as many autistic individuals have gastrointestinal problems as co-morbidities. This review emphasizes the role of altered gut microbiota observed frequently in autistic patients, and the mechanisms through which such alterations may trigger leaky gut.
Different bacterial metabolite levels in the blood and urine of autistic children, such as short-chain fatty acids, lipopolysaccharides, beta-cresol, and bacterial toxins, were reviewed. Moreover, the importance of selected proteins, among which are calprotectin, zonulin, and lysozyme, were discussed as biomarkers for the early detection of leaky gut as an etiological mechanism of ASD through the less integrative gut-blood-brain barriers. Disrupted gut-blood-brain barriers can explain the leakage of bacterial metabolites in these patients.
Although the cause-to-effect relationship between ASD and altered gut microbiota is not yet well understood, this review shows that with the consumption of specific diets, definite probiotics may represent a noninvasive tool to reestablish healthy gut microbiota and stimulate gut health. The diagnostic and therapeutic value of intestinal proteins and bacterial-derived compounds as new possible biomarkers, as well as potential therapeutic targets, are discussed.
创新研究凸显了自闭症谱系障碍(ASD)与肠道微生物群之间可能存在的联系,因为许多自闭症个体都伴有胃肠道问题。本综述强调了自闭症患者中经常观察到的肠道微生物群改变的作用,以及这种改变可能引发肠漏的机制。
综述了自闭症儿童血液和尿液中不同的细菌代谢产物水平,如短链脂肪酸、脂多糖、对甲酚和细菌毒素。此外,还讨论了选定蛋白质(包括钙卫蛋白、闭合蛋白和溶菌酶)作为生物标志物的重要性,这些生物标志物可通过不太完整的肠-血-脑屏障早期检测肠漏,而肠漏是ASD的一种病因机制。肠道屏障破坏可解释这些患者中细菌代谢产物的渗漏。
虽然ASD与肠道微生物群改变之间的因果关系尚未完全明确,但本综述表明,通过食用特定饮食,某些益生菌可能是重建健康肠道微生物群和促进肠道健康的一种非侵入性工具。文中还讨论了肠道蛋白质和细菌衍生化合物作为新的潜在生物标志物以及潜在治疗靶点的诊断和治疗价值。